JAZZ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
JAZZ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-27), Jazz Pharmaceuticals's current share price is $109.46. Jazz Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $10.94. Jazz Pharmaceuticals's Cyclically Adjusted Price-to-FCF for today is 10.01.
The historical rank and industry rank for Jazz Pharmaceuticals's Cyclically Adjusted Price-to-FCF or its related term are showing as below:
During the past years, Jazz Pharmaceuticals's highest Cyclically Adjusted Price-to-FCF was 484.64. The lowest was 9.82. And the median was 24.86.
JAZZ's Cyclically Adjusted Price-to-FCF is ranked better thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Jazz Pharmaceuticals's adjusted free cash flow per share data for the three months ended in Dec. 2023 was $1.999. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $10.94 for the trailing ten years ended in Dec. 2023.
The historical data trend for Jazz Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jazz Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted Price-to-FCF | Get a 7-Day Free Trial | 16.55 | 14.47 | 11.62 | 11.83 | 11.24 |
For the Biotechnology subindustry, Jazz Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Jazz Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
Jazz Pharmaceuticals's Cyclically Adjusted Price-to-FCF for today is calculated as
Cyclically Adjusted Price-to-FCF | = | Share Price | / | Cyclically Adjusted FCF per Share |
= | 109.46 | / | 10.94 | |
= | 10.01 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jazz Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:
For example, Jazz Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | 1.999 | / | 120.1096 | * | 120.1096 | |
= | 1.999 |
Current CPI (Dec. 2023) = 120.1096.
Jazz Pharmaceuticals Quarterly Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
201403 | -1.022 | 100.573 | -1.221 |
201406 | 0.991 | 100.773 | 1.181 |
201409 | 0.743 | 100.474 | 0.888 |
201412 | 1.666 | 99.576 | 2.010 |
201503 | 1.305 | 99.975 | 1.568 |
201506 | 2.022 | 100.573 | 2.415 |
201509 | 2.691 | 100.274 | 3.223 |
201512 | 1.849 | 99.676 | 2.228 |
201603 | 2.243 | 99.676 | 2.703 |
201606 | -0.428 | 101.072 | -0.509 |
201609 | 1.871 | 100.274 | 2.241 |
201612 | 2.940 | 99.676 | 3.543 |
201703 | 2.631 | 100.374 | 3.148 |
201706 | 2.033 | 100.673 | 2.426 |
201709 | 1.718 | 100.474 | 2.054 |
201712 | 3.067 | 100.075 | 3.681 |
201803 | 2.619 | 100.573 | 3.128 |
201806 | 1.249 | 101.072 | 1.484 |
201809 | 3.517 | 101.371 | 4.167 |
201812 | 3.525 | 100.773 | 4.201 |
201903 | 2.381 | 101.670 | 2.813 |
201906 | 1.866 | 102.168 | 2.194 |
201909 | 4.664 | 102.268 | 5.478 |
201912 | 1.409 | 102.068 | 1.658 |
202003 | 0.945 | 102.367 | 1.109 |
202006 | 1.375 | 101.769 | 1.623 |
202009 | 4.348 | 101.072 | 5.167 |
202012 | 2.556 | 101.072 | 3.037 |
202103 | 4.844 | 102.367 | 5.684 |
202106 | 0.581 | 103.364 | 0.675 |
202109 | 4.044 | 104.859 | 4.632 |
202112 | 2.727 | 106.653 | 3.071 |
202203 | 2.729 | 109.245 | 3.000 |
202206 | 3.494 | 112.734 | 3.723 |
202209 | 6.736 | 113.431 | 7.133 |
202212 | -0.672 | 115.425 | -0.699 |
202303 | 4.282 | 117.618 | 4.373 |
202306 | 3.957 | 119.611 | 3.973 |
202309 | 4.249 | 120.708 | 4.228 |
202312 | 1.999 | 120.110 | 1.999 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
Thank you for viewing the detailed overview of Jazz Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Jennifer E. Cook | director | C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Mark Douglas Smith | director | C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577 |
Neena M Patil | officer: SVP, General Counsel | JAZZ PHARMACEUTICALS, 3170 PORTER DRIVE, PALO ALTO CA 94304 |
Patricia Carr | officer: VP, Finance& PAO | JAZZ PHARMACEUTICALS, 3170 PORTER DRIVE, PALO ALTO CA 94304 |
Heather Ann Mcsharry | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Patrick G Enright | director, 10 percent owner | CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025 |
Norbert G Riedel | director | BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015 |
Catherine A. Sohn | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Rick E Winningham | director | 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Peter Gray | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Anne Oriordan | director | HOUSE 120, TAI HANG HAU VILLAGE, LOBSTER BAY, CLEARWATER BAY K3 HK |
Kenneth W O'keefe | director | C/O BEECKEN PETTY O'KEEFE & COMPANY, 131 S. DEARBORN STREET, SUITE 2800, CHICAGO IL 60603 |
Mary Elizabeth Henderson | officer: SVP, Technical Operations | 3170 PORTER DRIVE, PALO ALTO CA 94304 |
Renee D Gala | officer: EVP & CFO | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Kim Sablich | officer: EVP & GM, North America | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005 |
From GuruFocus
By ACCESSWIRE • 10-06-2023
By PRNewswire • 08-24-2023
By PRNewswire • 09-13-2023
By PRNewswire • 12-01-2023
By PRNewswire • 08-09-2023
By PRNewswire • 09-12-2023
By PRNewswire • 11-14-2023
By PRNewswire PRNewswire • 05-31-2023
By PRNewswire • 10-16-2023